Alzheimer's Disease - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Alzheimer's Disease - Pipeline Review, H2 2013 market report to its offering
Alzheimer's Disease - Pipeline Review, H2 2013


, 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Alzheimer's Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
OXIS International, Inc.
Shionogi & Co., Ltd.
NsGene A/S
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Merck & Co., Inc.
United Biomedical, Inc.
Taisho Pharmaceutical Co., Ltd.
Euroscreen S.A.
Applied NeuroSolutions, Inc.
ExonHit Therapeutics SA
Plexxikon Inc.
Avineuro Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novartis AG
Isotechnika Pharma Inc.
Samyang Corporation
Aphios Corporation
Alzhyme Ltd.
EnVivo Pharmaceuticals
Astellas Pharma Inc.
Chiesi Farmaceutici SpA
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Elan Corporation, plc
H Lundbeck A/S
Jeil Pharmaceutical Co., Ltd.
Laboratoires Pierre Fabre SA
Les Laboratoires Servier
Octapharma AG
Orion Corporation
Pain Therapeutics, Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Toyama Chemical Co. Ltd
Hadasit Medical Research Services & Development Ltd
Addex Pharmaceuticals
Evotec Aktiengesellschaft
Anavex Life Sciences Corp.
Neuralstem, Inc.
Amicus Therapeutics, Inc.
AVANIR Pharmaceuticals
BELLUS Health Inc
Bionomics Limited
ReGenX Biosciences, LLC
Nymox Pharmaceutical Corporation
Osta Biotechnologies Inc.
Paladin Labs Inc.
Cortex Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
ACADIA Pharmaceuticals Inc.
ProteoTech, Inc.
Prana Biotechnology Limited
Lipoxen PLC
Biotie Therapies Corp.
Transition Therapeutics Inc.
Neurim Pharmaceuticals (1991) Ltd.
Theravance, Inc.
Resverlogix Corp.
Suven Life Sciences Ltd.
MediPost Co., Ltd.
Summit Corporation plc
CrystalGenomics, Inc.
Newron Pharmaceuticals S.p.A.
Mithridion, Inc.
Teikoku Pharma USA, Inc.
Labtec GmbH
Xel Pharmaceuticals, Inc.
TauRx Therapeutics Ltd
Ceregene, Inc.
CoMentis, Inc.
AC Immune SA
Humanetics Corporation
Accera, Inc.
Sonexa Therapeutics, Inc.
D-Pharm Ltd.
Functional Genetics, Inc.
StemCells, Inc.
Proteome Sciences Plc
Upsher-Smith Laboratories, Inc.
Probiodrug AG
Snowdon Inc.
Domain Therapeutics
Pharmagenesis, Inc.
Acumen Pharmaceuticals, Inc.
Wellstat Therapeutics Corporation
Celon Pharma Sp. z o.o.
ALSP, Inc.
CoLucid Pharmaceuticals, Inc.
Metabolic Solutions Development Co.
Hawthorn Pharmaceuticals, Inc.
Cognition Therapeutics, Inc.
BioArctic Neuroscience AB
Vaxin, Inc.
QR Pharma, Inc.
NeuroNascent, Inc.
Siena Biotech S.p.A.
Virobay Inc.
SeneXta Therapeutics SA
KineMed, Inc.
ManRos Therapeutics
Intellect Neurosciences, Inc.
Transtech Pharma, Inc.
Xencor, Inc.
Adeona Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc.
Stemedica Cell Technologies, Inc.
Targacept, Inc.
AB Science
Vitae Pharmaceuticals, Inc.
Tautatis Incorporated
Medisyn Technologies, Inc.
TheraCarb Inc.
Proteostasis Therapeutics, Inc.
Medestea Research & Production S.p.A.
M's Science Corporation
NasVax Ltd.
BrainCells Inc.
Stelic Institute & Co.
EndoCeutics, Inc.
Pharnext SAS
PharmatrophiX, Inc.
TREVENTIS Corporation
Ascenion GmbH
Phenomenome Discoveries, Inc.
Satori Pharmaceuticals Inc.
Inserm Transfert SA
Sinil Pharma Ltd.
Heptares Therapeutics Ltd.
Signum Biosciences, Inc.
Neuraltus Pharmaceuticals, Inc.
Femta Pharmaceuticals, Inc.
ArmaGen Technologies, Inc.
B&C Biopharm
Axon Neuroscience GmbH
RNL BIO Co., Ltd.
Clera Inc.
BioChromix Pharma AB
NAL Pharmaceuticals Ltd.
Laila Pharmaceuticals Pvt. Ltd.
Serometrix, LLC
Archer Pharmaceuticals, Inc.
Varinel, Inc.
Cognosci, Inc.
Reviva Pharmaceuticals Inc.
VLP Biotech, Inc.
RaQualia Pharma Inc.
Naurex, Inc.
PharmaNeuroBoost N.V.
America Stem Cell, Inc.

To view the table of contents for this market research report please visit